Cargando…
Ringhalexin from Hemachatus haemachatus: A novel inhibitor of extrinsic tenase complex
Anticoagulant therapy is used for the prevention and treatment of thromboembolic disorders. Blood coagulation is initiated by the interaction of factor VIIa (FVIIa) with membrane-bound tissue factor (TF) to form the extrinsic tenase complex which activates FX to FXa. Thus, it is an important target...
Autores principales: | Barnwal, Bhaskar, Jobichen, Chacko, Girish, Vallerinteavide Mavelli, Foo, Chun Shin, Sivaraman, J., Kini, R. Manjunatha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4865804/ https://www.ncbi.nlm.nih.gov/pubmed/27173146 http://dx.doi.org/10.1038/srep25935 |
Ejemplares similares
-
Exactin: A specific inhibitor of Factor X activation by extrinsic tenase complex from the venom of Hemachatus haemachatus
por: Girish, Vallerinteavide Mavelli, et al.
Publicado: (2016) -
Identification and Structural Characterization of a New Three-Finger Toxin Hemachatoxin from Hemachatus haemachatus Venom
por: Girish, Vallerinteavide Mavelli, et al.
Publicado: (2012) -
A general approach to protein folding using thermostable exoshells
por: Sadeghi, Samira, et al.
Publicado: (2021) -
Gastrointestinal Tract Stabilized Protein Delivery Using Disulfide Thermostable Exoshell System
por: Sadeghi, Samira, et al.
Publicado: (2022) -
Nanoencapsulation as a General Solution for Lyophilization of Labile Substrates
por: Vallerinteavide Mavelli, Girish, et al.
Publicado: (2021)